ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

Slides:



Advertisements
Similar presentations
Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.
Advertisements

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Global HIV Resistance: The Implications of Transmission
Modified Directly Observed Therapy for First Virologic Failure: ACTG A5234 PI Dr A Chisada Presenter: Dr W Samaneka MBChB, MSc UZ-UCSF ARD 17 April 2015.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
M. Ekstrand 1,2,3, A. Shet 2,4, S. Chandy 4, G. Singh 4, R. Shamsundar 4, V. Madhavan 5, S. Saravanan 5, N. Kumarasamy 5 1 University of California, San.
The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
Are Patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara JCRC HAART Clinic.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
1 Outcomes of a psychosocial support programme for HIV- infected young women R. Phillip Newlands Clinic, Harare, Zimbabwe.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Center for Studies of Addiction, University of Pennsylvania, USA
Module 1: Principles of Viral Load Monitoring
Switch to PI/r monotherapy
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Learning objectives Define HIV treatment goals
How differentiated care supports “Tx all” and Dr
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
Title Factors associated with viral suppression among adolescents living with HIV in Cambodia “No conflicts of interest to declare”
2017 Key Considerations for adolescents and children & Key populations
Etravirine in Treatment Experienced DUET-2 (TMC125-C216)
Module 4: Role Playing and Case Discussions
Validating Definitions of Antiretroviral Treatment Failure in Malawi
The Effect of Family Social Intervention on Treatment Response in Children with HIV Infection Francine Cheng DO, Janak Patel MD, Debbie Konopik SWA, and.
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Utilizing research as an opportunity to strengthen
VL patient support: General education at different levels
Risk of Treatment Failure: Patient Support approaches and strategies
2nd line treatment counseling for adult patients
Chloe Orkin British HIV Association Queen Mary University London
Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana ¹Obiri-Yeboah Dorcas, School of Medical Sciences,
The role of CD4 in patient monitoring Amsterdam July 2018
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,
Experiences & outcomes of group psychotherapy as an antiretroviral adherence support intervention among young people failing ART at Newlands Clinic, Harare,
Comparison of INSTI vs INSTI
HIV.
U=U Guidance for Implementation in Clinical Settings
Update on global progress in ART
For a healthy Zambia.
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote

Acknowledgements  Prof Ruedi Luethy, Dr C Chimbetete, Dr M. Pascoe, Dr C Kunzekwenyika and Mr T Shamu  Newlands clinic staff  Newlands clinic patients

Presentation Outline  The Newlands Clinic  Viral load monitoring  Summary of the review  Results  Conclusion  Recommendations

The Newlands Clinic  The Clinic is a family centred,nurse led clinic that treat HIV positive patients.  Currently we are looking after 5067 patients.  84%(4271) are on ART of which 13%(567) are on second line

Monitoring Patients on ART  Virological monitoring is the best way of monitoring a patient on ART  After starting a patient on ART VL suppression is expected to be achieved with 6 months  Optimal adherence is essential for this to be achieved

Interpretation of VL  VL can either be undetectable or detectable  Conventionally - undetectable VL is <50copies/ml depending on the type of machine and methodology  However at NC the lower limit of detection is 37copies/ml (Siemens kPCR)

Low Level Viraemia  LLV is when HIV-1 RNA is between copies/mL in patients who had achieved viral suppression on antiretroviral therapy  Patients with LLV are at an increased risk of developing subsequent virological failure  Ideally a patient should have a persistently suppressed VL

Virological Failure and High Level Viraemia  High level viraemia is defined as VL>1000copies/ml  Virological failure is defined as 2 consecutive viral load measurements >1000copies/ml  This happens either due to poor adherence or development of drug resistance which can either be acquired or transmitted

Virological Failure  Ongoing viral replication in the presence of suboptimal ART promotes the selection of further drug resistance mutations.  Among patients experiencing persistent low- level viraemia, those with viraemia >400 copies/mL and a history of ART experience are more likely to have virological failure.

Viral Load Re-suppression  A study in Khayelitsha,South Africa showed that 68% of patients failing second line therapy re-suppressed within 3months of enhanced adherence support(Garone et al,2013).

NC SOP for VL Monitoring  All patients have baseline VL at ART commencement  Routine VL measurements done every 6 months  Targeted VL offered to patients: o With suspected lack of adherence o With a documented decrease of CD4 by 50% from a measured peak CD4 o With a new or relapsing OI o Unexplained weight loss > 10%

Viral Load (VL) Monitoring  Routing VL is done at baseline, after 6 months and 6 monthly thereafter  If VL is found to be detectable it is repeated within 3 months  Patient failing first line are then switched to 2 nd line  Patient failing 2 nd line undergo enhanced adherence counselling while we wait for 3 rd line

3 rd Line Regimen  MOHCC developing a protocol for patients failing 2 nd line ART and guidelines for 3 rd line therapy  2 drugs to be used for 3 rd line are now available  Raltegravir and Darunavir/ritonavir  Still deliberating on the 3 rd drug  NC is one of the 4 referral centres that will be managing patients on 3 rd line

Objectives of the Review  To determine the level of viraemia in adults above the age of 25 years who are on 2 nd line ART  To determine the effect of enhanced adherence support on the viral load

Methods  All adults patients on 2 nd line with a viral load test done from the period 1 August 2013 to 1 June 2014 were reviewed

Results  371 patients were adults taking second line ART

Patients on 2 nd line >6months  59%(221) of the adults have been on 2 nd line for at least 6 months  Minimum duration on ART was 9 months and maximum 70 months

Adults Patients on 2 nd Line ART

Adults on 2 nd line(>6months): virological status(n=221)

Duration on 2 nd Line (n=221)

Intervention for Patients Detectable on 2 nd Line  All 69(31%) patients are supposed to go through 3 month period of enhanced adherence counselling  The first 22 patients were asked to attend weekly adherence support groups and have completed their 3 months  The baseline and end of intervention VL were then compared

Effect of Enhanced Adherence Counselling Patient IDPre-intervention VLPost intervention

Reasons for Poor Adherence from the patients  Stigma(7)  Non disclosure(4)  Psychological problems(especially depression)(6)  Old age and lack of support(2)  Substance abuse(alcohol)(4)  Ignorance(2)

Conclusions  18% of patients on 2 nd line are virologically failing treatment(according to national and WHO guidelines)  13% have LLV and at risk of eventually progressing to virological failure  Adherence is the major cause of detectable viral load  Enhanced counselling may lead to re- suppression of VL

Recommendations  Routine VL should be done for all patients on ART  Strategies for maintain optimal adherence must be achieved for effective VL suppression  Enhanced adherence support for patients with detectable VL on 2 nd line should be done before a patient can be diagnosed of treatment failure requiring 3 rd line

THE END